Evidence map›Paper›PMID 41714572›Full record

ArticleJournal of imaging informatics in medicine2026

BreasTransNeXt: An Enhanced Multi-Module Vision Transformer For Early Breast Cancer Diagnosis.

Hakan Acikgoz, Alper Aytekin, Sevgi Gezici

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of imaging informatics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hakan AcikgozDepartment of Software Engineering, Faculty of Engineering, Architecture and Design, Kahramanmaras Istiklal University, Kahramanmaras, 46050, Turkey. hakan.acikgoz@istiklal.edu.tr.ORCID http://orcid.org/0000-0002-6432-7243
Alper AytekinDepartment of General Surgery, Faculty of Medicine, Gaziantep University, 27310, Gaziantep, Turkey.ORCID http://orcid.org/0000-0003-2872-5276
Sevgi GeziciDepartment of Medical Biology, Faculty of Medicine, Gaziantep University, 27310, Gaziantep, Turkey.ORCID http://orcid.org/0000-0002-4856-0221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) represents the most common and one of the most lethal malignancies among women globally, ranking second only to lung cancer in terms of mortality. Early diagnosis is critically important, as treatment outcomes are significantly improved when BC is identified at an initial stage. Although considerable research has been conducted on BC classification utilizing deep learning techniques, there remains a deficiency of comprehensive models that effectively integrate robust feature extraction with balanced learning methodologies. To address this limitation, we introduce BreasTransNeXt, a new hybrid deep learning framework that synergizes the convolutional inductive bias inherent in ConvFormer with the efficient global attention mechanisms of a hybrid transformer architecture, thereby facilitating robust multi-scale feature representation. Furthermore, to mitigate class imbalance and enhance model generalization, the BC dataset is augmented through the application of a Wasserstein Generative Adversarial Network with gradient penalty, which generates high-fidelity synthetic images for both malignant and healthy classes. Additionally, BreasTransNeXt incorporates a hybrid attention mechanism comprising of local, channel, and global branches, which are integrated via adaptive gating; this design enhances feature representation by capturing fine-grained lesion characteristics, inter-feature correlations, and long-range contextual dependencies. The proposed model is rigorously evaluated against traditional convolutional neural network approaches and state-of-the-art vision transformer architectures. Experimental findings demonstrate that BreasTransNeXt consistently outperforms these methods, achieving an accuracy of 0.9710, recall of 0.9808, precision of 0.9808, and F1-score of 0.9808, thereby underscoring its potential as a reliable tool for early BC detection.

Indexed as

Breast cancerDeep learningHybrid attentionVision transformerWasserstein Generative Adversarial Network

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.